Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Capricor Therapeutics Inc (CAPR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Capricor Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.150 +0.110    +2.18%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
5.300
+0.150
+2.913%
19:30:41 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 387,923
  • Bid/Ask: 5.050 / 5.300
  • Day's Range: 4.910 - 5.240
Capricor Therapeutics 5.150 +0.110 +2.18%

Capricor Therapeutics Inc Company Profile

 
Get an in-depth profile of Capricor Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

102

Equity Type

ORD

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Contact Information

Address 10865 Road to the Cure Suite 150
San Diego, 92121
United States
Phone 858 727 1755
Fax -

Top Executives

Name Age Since Title
Frank Isaac Litvack 67 2012 Executive Chairman of the Board
Linda Marbán 60 2010 Co-Founder, President, CEO & Director
Eduardo Marbán - - Co-Founder & Chairman of Scientific Advisory Board
Oscar Henry Mayer - - Member of Scientific Advisory Board
Barry J. Byrne - - Member of Scientific Advisory Board
Thomas Voit - - Member of Scientific Advisory Board
Eugenio Mercuri - - Member of Scientific Advisory Board
Earl M. Collier 77 2013 Independent Director
David Brian Musket 66 2013 Independent Director
Francesco Muntoni - - Member of Scientific Advisory Board
George W. Dunbar 77 2013 Independent Director
Craig McDonald - - Member of Scientific Advisory Board
Michelle Eagle - - Member of Scientific Advisory Board
Pat Furlong - - Member of Scientific Advisory Board
Philip J. Gotwals 61 2023 Independent Director
Paul Gisbert Auwaerter 62 2023 Independent Director
Karimah Es Sabar 66 2021 Independent Director
Michael Kelliher 47 2023 Independent Director
Timothy R. Franson 72 2023 Member of the Scientific Advisory Board
Michael Taylor - 2018 Member of Scientific Advisory Board
Suzanne Hendrix - 2023 Member of Scientific Advisory Board
Chet Villa - 2023 Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CAPR Comments

Write your thoughts about Capricor Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Haswdt Rswuntr
Haswdt Rswuntr Oct 10, 2022 4:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bravo
Giuseppe Giannachi
Giuseppe Giannachi Mar 29, 2022 5:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The clinical trials news seemed good, but the stock got hit hard. Any ideas for today? Thanks.
TITH Vicheth
TV32 Jan 25, 2022 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$10, $Capr has Cap $60M, Contract $705M, Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million.
Cool Coal
coolcoal May 04, 2021 1:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nevermind
Cool Coal
coolcoal Apr 29, 2021 10:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
Ермуханбет Селеубаев
Ермуханбет Селеубаев Nov 11, 2020 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should buy?
Richard Fortin
Richard Fortin Nov 11, 2020 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is a company that leaves investors without any news or updates. Linda mentions FDA approval "Soon" which is years. Linda was mentioning about her Cap 1002 for the past years and repeats the same garbage over and over. They are not doing nothing.
Chris Leverett
Chris Leverett Sep 22, 2020 7:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone know when the clinical news is supposed to be released?
brian denny
brian denny Sep 22, 2020 7:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will be some news tomorrow afternoon at 4.30
Chuck Foy
Chuck Foy Sep 10, 2020 8:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Where do we go from here?
Brian Denny
Brian Denny Sep 10, 2020 8:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up up and away!!!! Gonna be a fun couple of weeks
Cookie Crumbler
Cookie Crumbler Sep 10, 2020 8:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
down and under !
Steven Re
Steven Re Aug 13, 2020 10:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
where is CAPR headed?
Paul Chittum
Paul Chittum Aug 09, 2020 6:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
prediction for eom?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email